Needham Reiterates Buy on Vaxcyte, Maintains $95 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer reiterates a Buy rating on Vaxcyte (NASDAQ:PCVX) and maintains a $95 price target.
August 07, 2024 | 9:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer reiterates a Buy rating on Vaxcyte and maintains a $95 price target.
The reiteration of a Buy rating and the maintenance of a $95 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100